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Postprogression Treatments? An Application in Advanced Non–
Small Cell Lung Cancer
Mahmoud Hashim, MPH1,*, Boris M. Pfeiffer, PhD2, Robert Bartsch, MSc1, Maarten Postma, PhD3,
Bart Heeg, PhD1
1Ingress-health, Rotterdam, The Netherlands; 2Merck KgaA, Darmstadt, Germany; 3University of Groningen, Groningen,
The NetherlandsA B S T R A C TBackground: In previous studies, correlation between overall survival
(OS) and surrogate endpoints like objective response rate (ORR) or
progression-free survival (PFS) in advanced non-small cell lung cancer
(NSCLC) was poor. This can be biased by crossover and postprogres-
sion treatments. Objectives: To evaluate the relationship between
these two surrogate endpoints and OS in advanced NSCLC studies
that did not allow for crossover or reported balanced post-progression
treatments. Methods: A systematic review in patients with advanced
NSCLC receiving second- and further-line therapy was performed. The
relationship between the absolute difference in ORR or median PFS
(mPFS) and the absolute difference in median OS (mOS) was assessed
using the correlation coefﬁcient (R) and weighted regression models.
The analysis was repeated in predeﬁned data cuts based on crossover
and balance of postprogression treatments. When the upper limit of
R’s 95% conﬁdence interval (CI) was more than 0.7, the surrogate
threshold effect (STE) was estimated. Results: In total, 146 random-
ized clinical trials (43,061 patients) were included. The mean ORR,
mPFS, and mOS were 12.2% ± 11.2%, 3.2 ± 1.3 months, and 9.6 ± 4.1
months, respectively. The correlation coefﬁcients of ORR and mPFSee front matter Copyright & 2018, International S
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rlands.were 0.181 (95% CI 0.016–0.337) and 0.254 (95% CI 0.074–0.418),
respectively, with mOS. Nevertheless, in trials that did not allow
crossover and reported balanced postprogression treatments, the
correlation coefﬁcients of ORR and mPFS were 0.528 (95% CI 0.081–
0.798) and 0.778 (95% CI 0.475–0.916), respectively, with mOS. On the
basis of STE estimation, in trials showing signiﬁcant treatment effect
size of 41.0% or more ORR or 4.15 or more mPFS months, OS beneﬁt
can be expected with sufﬁcient certainty. Conclusions: Crossover and
postprogression treatments may bias the relationship between surro-
gate endpoints and OS. Presented STE calculation can be used to
interpret treatment effect on either ORR or PFS when used as primary
endpoints.
Keywords: crossover, non–small cell lung cancer, overall survival,
surrogate endpoints validation.
Copyright & 2018, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Overall survival (OS) is the criterion standard endpoint in cancer
trials and is used to establish clinical beneﬁt in support of
regulatory and reimbursement applications [1–4]. Nevertheless,
trials using OS as a primary endpoint need substantial sample
sizes and extensive follow-up. In addition, the effects of cross-
over or unbalanced postprogression treatments may introduce
bias or underestimate the treatment effect on OS [5,6]. An
alternative surrogate endpoint for OS is progression-free survival
(PFS). Regulatory agencies endorse PFS as a relevant endpoint in
cancer trials [1,2,7]. In contrast to OS, PFS is not sensitive to
postprogression treatments and has the advantage of assessingthe duration of tumor response [5]. Objective response rate (ORR)
is another potential surrogate endpoint. Compared with PFS, ORR
does not assess response duration. The use of PFS and ORR as
surrogate endpoints for OS would require that they be validated
for this use [8]. Nevertheless, uncertainties regarding their asso-
ciation with OS and the potential for bias due to subjectivity in
the assessment of ORR and PFS limit their use [7].
To our knowledge, only the Institute for Quality and Efﬁciency
in Health Care (IQWiG) has issued a guidance document for
surrogate endpoint validation in oncology [4]. The IQWiG recom-
mends a stringent deﬁnition of surrogacy on the basis of the
correlation coefﬁcient (R). IQWiG states that if the lower limit of
the 95% conﬁdence interval (CI) of R is 0.85 or higher, validity ofociety for Pharmacoeconomics and Outcomes Research (ISPOR).
BY-NC-ND license
lth Economics and Real-World Evidence, Hofplein 20, Rotterdam
V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) 9 – 1 710the surrogate is suggested, but that the surrogate is not valid if
the upper limit of the 95% CI is 0.7 or less [4]. Otherwise, the
validity of the surrogate remains unclear; in this situation, IQWiG
recommends estimating the surrogate threshold effect (STE) [4,9].
STE is deﬁned as the minimum treatment effect on the surrogate
necessary to predict a statistically signiﬁcant nonzero effect on
the true endpoint [9]. STE can be used to interpret the treatment
effect on the surrogate endpoint.
A few studies in non–small cell lung cancer (NSCLC) have
investigated the surrogacy of ORR or PFS to OS at the trial level
[6,10–13]. These studies reported low correlations between PFS or
ORR and OS. None of them included a stratiﬁed analysis based on
the exclusion of studies allowing crossover or reporting unbal-
anced postprogression treatments. Stratifying studies on the
basis of crossover has been done in other tumor types [14–16].
Delea et al. [15] assessed the surrogacy of PFS to OS in metastatic
renal cell carcinoma trials. The correlation coefﬁcient was greater
in studies that did not allow/require crossover versus those that
did allow/require crossover: correlation coefﬁcients were esti-
mated to be 0.50 and 0.28, respectively. Similarly, and to a less
extent, greater correlation coefﬁcients were observed in endpoint
validation studies for metastatic melanoma and metastatic color-
ectal cancer after the removal of studies that did not allow/
require crossover [14,16]. Hence, investigating the effect of cross-
over and postprogression treatments on the surrogacy of ORR or
PFS to OS in NSCLC is warranted.
This study aimed to evaluate ORR and PFS as surrogate endpoints
for OS in trials involving patients with advanced NSCLC receiving
second- and further-line therapy. Then, the impact of crossover and
unbalanced postprogression treatments on surrogacy was assessed.Methods
Systematic Literature Review
The systematic literature reviewwas conducted and reported accord-
ing to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses statement [17]. Two different bibliographic databases,
PubMed and Embase, were used to identify published randomized
clinical trials involving patients with stage IIIB/IV NSCLC receiving
second- and further-line therapy. The search was conducted on July
28, 2016; no limitation on publication date was imposed.
A detailed search strategy (search syntax and eligibility cri-
teria) is presented in Appendix Table 1 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2017.07.011. One investi-
gator reviewed the titles/abstracts of retrieved articles sequen-
tially using the predeﬁned eligibility criteria (see Appendix Table 1
in Supplemental Materials). Subsequently, two investigators
reviewed the full text of any article that appeared to meet the
eligibility criteria; disagreement was resolved by consulting with a
third investigator. References in publications reviewed at the full-
text stage were evaluated to identify further relevant trials.
Upon agreement on the ﬁnal list of included trials, one
investigator extracted data from the included trials into a pre-
deﬁned Microsoft Excel template. Subsequently, another inves-
tigator validated the extracted data by re-extracting them. The
following data were extracted: trial identiﬁcation items (e.g.,
PubMed identiﬁer, ﬁrst author, year, trial phase, registration
identiﬁer, and trial acronym), interventions and target popula-
tion, basic patient and disease characteristics (e.g., age, sex,
performance status, disease stage, histology, metastasis, and
number of previous lines of therapy), additional information
(e.g., use of biomarkers and crossover), and data needed for
endpoint validation (number of patients in each treatment arm,
ORR, PFS, and OS). Risk of bias in individual studies was assessed
using the Jadad scale [18].Assessment of Publication Bias
The risk of bias across studies was assessed using funnel plots. In
this study, trial size as a measure of precision was plotted on the
y-axis, and treatment effect (absolute difference) on ORR, PFS,
and OS was plotted on the x-axis. In the absence of publication
bias, the plot should resemble a symmetrical inverted funnel [19].
Statistical Analysis
Primary analysis
The relationship between the absolute difference in ORR and
median PFS (mPFS) and the absolute difference in median OS
(mOS) was assessed using the correlation coefﬁcient (R) and
weighted linear regression models. A weighted linear regression
model was ﬁtted for the following two analyses: treatment effect
on ORR, with the absolute difference in ORR (%) as an independ-
ent variable (predictor) and the treatment effect on OS (absolute
difference in mOS in months) as a dependent variable; and
treatment effect on PFS, with the absolute difference in mPFS
(months) as an independent variable (predictor) and the treat-
ment effect on OS (absolute difference in mOS in months) as a
dependent variable. Analyses were weighted by trial size, as in
previous endpoint validation studies [10,13,15,20–22].
Analyses were repeated using the absolute difference in ORR
(%) or PFS hazard ratio (HR) and OS-HR because HRs might
capture treatment effects not captured by median survival times.
We carried out log transformation of HR. Log transformation can
be used to make right-skewed distributions less skewed. Treat-
ment effect on ORR is usually reported as the absolute difference
in ORR (%). For that reason and for the ease of interpretation, we
used it in both analyses with OS (mOS and OS-HR). Residual
versus predicted plots were inspected and diagnostic tests for
normality and heteroscedasticity (nonconstant error variance)
were carried out to assess consistency with the assumptions of
linear regression.
First, the analysis was conducted for all trials. Trials that had
allowed crossover or in which postprogression treatments were
unbalanced could underestimate OS beneﬁt and subsequently
bias surrogacy evaluation. Typically, phase III trials are
adequately powered for endpoints such as PFS and OS, whereas
phase II trials tend to be smaller and powered for safety
endpoints or ORR. Thus, phase III trials might provide more
information regarding the treatment effect on these endpoints.
Therefore, second, on the basis of reported postprogression
treatments, we examined trial-level surrogacy in all phase III
trials (data cut A), in phase III trials excluding those with per-
protocol crossover (data cut B), in phase III trials excluding those
with both per-protocol and off-protocol crossover (data cut C),
and in phase III trials excluding those with crossover, unbalanced
postprogression treatments, or no information with regard to
postprogression treatments (data cut D).
Trials that reported both the independent (the surrogate
endpoint) and the dependent (the true endpoint) variables in
both treatment arms were included in the analyses. For trials that
included more than two treatment arms, the experimental arm
was compared with a randomly chosen control arm within the
same study to avoid analysis of correlated data, that is, including
a treatment arm twice in the analysis. For trials that reported
response in the evaluable population rather than in the inten-
tion-to-treat population, the denominator was adjusted to indi-
cate the intention-to-treat population.
Assessing surrogacy and STE estimation
In cases in which the validity of the surrogate endpoint is
deemed to be “unclear” following IQWiG guidelines [4], STE
estimation is recommended to interpret treatment effect on the
Table 1 – Basic population characteristics in all included trials and prespeciﬁed data cuts based on reported postprogression therapies.
Characteristic All trials (n ¼ 146) Data cut A (n ¼ 59) Data cut B (n ¼ 54) Data cut C (n ¼ 38) Data cut D (n ¼ 18)
Valid (n) Mean ± SD Valid (n) Mean ± SD Valid (n) Mean ± SD Valid (n) Mean ± SD Valid (n) Mean ± SD
Age (y), median* 288 61.3 ± 3.2 116 61.2 ± 3.3 106 61.2 ± 2.9 76 61.7 ± 2.8 36 61.9 ± 3.6
Male (%)* 292 63.7 ± 13.4 118 64.9 ± 13.5 108 65.5 ± 11.5 76 66.1 ± 11.1 36 60.8 ± 7.4
ECOG 0 or 1 (%)* 278 90.2 ± 12.2 116 91.2 ± 8 106 91.4 ± 8.2 74 90 ± 8.7 36 91.7 ± 8
Adenocarcinoma (%)* 238 63.3 ± 18.6 96 65.2 ± 18 90 63.7 ± 17.2 62 62.3 ± 16.7 32 71.2 ± 15
ORR (%)* 290 12.2 ± 11.2 118 12.4 ± 12.7 108 11.4 ± 11.3 76 11.3 ± 12.3 36 13.4 ± 14.5
PFS (mo)* 236 3.2 ± 1.3 100 3.2 ± 1.4 90 3.1 ± 1.3 60 3.1 ± 1.3 34 3.3 ± 1.4
OS (mo)* 282 9.6 ± 4.1 118 10 ± 4.2 108 9.6 ± 3.7 76 9.1 ± 3.8 36 10.4 ± 4.3
Jadad scale† 146 2.7 ± 1.0 59 3 ± 1.1 54 3.1 ± 1.1 38 3.1 ± 1.1 18 3.7 ± 1.3
Sample size† 146 294.9 ± 321.2 59 548.3 ± 382.3 54 567.7 ± 391.8 38 594.1 ± 439.9 18 741.6 ± 431.3
Note. Data cuts based on reported postprogression treatments: data cut A, phase III trials; data cut B, phase III trials excluding those with per-protocol crossover; data cut C, phase III trials
excluding those with both per-protocol and off-protocol crossover; and data cut D, phase III trials excluding those with crossover, unbalanced postprogression treatments or insufﬁcient
information.
ECOG, Eastern Cooperative Oncology Group, performance status; n, number of observations; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
⁎ Valid number of treatment arms with reported observation.

























V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) 9 – 1 712surrogate endpoint. STE is the minimum treatment effect on the
surrogate necessary to predict a statistically signiﬁcant nonzero
effect on the true endpoint [9]. The STE calculation allows
threshold values for the decision as to whether an observed
effect on the surrogate would predict (with sufﬁcient certainty)
an effect on the endpoint of interest to be speciﬁed [9]. To draw
such a conclusion, the lower conﬁdence limit of the treatment
effect on the surrogate must be larger than the STE. To calculate
the STE, the regression line was plotted using the weighted linear
regression equation. Then, 95% prediction intervals were plotted.
The value on the x-axis, the treatment effect on the surrogate, at
which the lower limit of the prediction interval (upper limit in the
case of relative treatment effect) meets a point corresponding to 0
on the y-axis (zero effect on the true endpoint) is the STE [9]. With
stronger correlation between the surrogate endpoint and the
hard endpoint, it is easier to reach the STE, for example, lower
incremental mPFS months or closer to 1 PFS-HR.Additional analyses
In addition to the likely bias due to the existence of crossover
and/or unbalanced postprogression treatments, other trial or
patient’s characteristics may bias the quantitative relationship
between surrogate endpoints and OS. Thus, ﬁrst we ﬁtted a
multivariate weighted linear regression model. Such analysis
would investigate whether the likely bias caused by crossover
and/or unbalanced postprogression treatments still holds after
adjustment for other available variables. The analysis was run







ΔORR (%) ΔOS, median
(mo)
All trials 140
Data cut A 59
Data cut B 54
Data cut C 38
Data cut D 18
OS-HR All trials 76
Data cut A 44
Data cut B 41
Data cut C 27
Data cut D 17
PFS, median
(mo)
OS, median (mo) All trials 114
Data cut A 50
Data cut B 45
Data cut C 30
Data cut D 17
PFS-HR OS-HR All trials 73
Data cut A 42
Data cut B 39
Data cut C 25
Data cut D 17
Note. Data cuts based on reported postprogression treatments: data cut A
B, phase III trials excluding those with per-protocol crossover; data cut C, p
crossover; and data cut D, phase III trials excluding those with crossover,
Δ, absolute difference; CI, conﬁdence interval; HR, hazards ratio; NA, n
progression-free survival; STE, surrogate threshold effect.
⁎ ΔORR (%).
† ΔPFS median months.
‡ PFS-HR.initial list of candidate independent (predictor) variables, in
addition to ΔPFS, included median age, male (%), Eastern Coop-
erative Oncology Group (performance status) 0 or 1 (%), adeno-
carcinoma (%), endothelial growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI) treatment (dummy variable), OS primary
endpoint (dummy variable), publication year, assessed Jadad
scale, and data cut D (dummy variable). Crossover and postprog-
ression treatments happen after progression. Therefore, the
simultaneous inﬂuence of ΔPFS and data cut D on OS is not
additive. This justiﬁes adding an interaction term between them
in the regression model.
Second, a logistic regression model was ﬁtted with data cut D
(yes ¼ 1; no ¼ 0) as the dependent variable. The same trial and
patient’s characteristics were considered as independent varia-
bles. This analysis should give more insight on the differences
between studies included and excluded in the data cut D.
All analyses were carried out using the statistical software
package R version 3.2.2 (R Foundation for Statistical Computing,
Vienna, Austria) and using Package “Surrogate” version 0.1-67
[23].Results
Systematic Literature Review
Of 6274 potentially relevant publications identiﬁed, 299 hits
qualiﬁed for full-text screening. After the full-text screening,










41,725 0.181 0.016 0.337 NA
32,348 0.131 0.000 0.375 NA
30,654 0.361 0.103 0.573 NA
22,574 0.445 0.146 0.669 NA
13,349 0.528 0.081 0.798 41.01*
30,570 0.172 0.000 0.383 NA
26,549 0.374 0.086 0.604 NA
25,534 0.399 0.104 0.629 NA
18,854 0.521 0.175 0.752 54.86*
13,194 0.164 0.000 0.597 NA
35,729 0.254 0.074 0.418 NA
27,579 0.260 0.000 0.502 NA
25,885 0.438 0.166 0.649 NA
18,634 0.741 0.520 0.869 3.74†
13,194 0.778 0.475 0.916 4.15†
29,907 0.402 0.190 0.579 NA
25,386 0.463 0.185 0.672 NA
24,371 0.461 0.170 0.678 NA
17,691 0.694 0.412 0.855 0.24‡
13,194 0.698 0.326 0.882 0.22‡
, all phase III trials regardless of postprogression treatments; data cut
hase III trials excluding those with both per-protocol and off-protocol
unbalanced postprogression treatments, or insufﬁcient information.
ot available; ORR, objective response rate; OS, overall survival; PFS,
Fig. 1 – Relationship between ΔORR (x-axis) and ΔOS (y-axis): (A) primary analysis (all trials); (B) phase III trials (data cut A);
(C) phase III trials excluding those with per-protocol crossover (data cut B); (D) phase III trials excluding those with both
per-protocol and off-protocol crossover (data cut C); and (E) phase III trials excluding those with crossover, unbalanced
postprogression treatments, or insufﬁcient information (data cut D). The solid line is the regression line. Red dashed lines are
the upper and lower limits of the 95% conﬁdence interval. Black dashed lines are the upper and lower bands of the 95%
prediction intervals. Circle size is proportionate to trial size. ORR, objective response rate; OS, overall survival.
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Fig. 2 – Relationship between ΔPFS (x-axis) and ΔOS (y-axis): (A) primary analysis (all trials); (B) phase III trials (data cut A);
(C) phase III trials excluding those with per-protocol crossover (data cut B); (D) phase III trials excluding those with both
per-protocol and off-protocol crossover (data cut C); and (E) phase III trials excluding those with crossover, unbalanced
postprogression treatments, or insufﬁcient information (data cut D). The solid line is the regression line. Red dashed lines are
the upper and lower limits of the 95% conﬁdence interval. Black dashed lines are the upper and lower limits of the 95%
prediction intervals. Circle size is proportionate to trial size. OS, overall survival; PFS, progression-free survival.
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Table 3 – Relationship between ΔPFS and ΔOS in phase III trials adjusted for patient and trial characteristics
(weighted multivariate linear regression model).
Variable Coefﬁcient P value 95% CI
Lower limit Upper limit
ΔPFS*
Data cut D (yes) 1.129 0.001 0.531 1.727
Data cut D (no) 0.379 0.071 −0.035 0.794
Age (y), median 0.170 0.018 0.031 0.308
ECOG 0 or 1 (%) 1.236 0.654 −4.342 6.814
Adenocarcinoma (%)† −1.599 0.287 −4.612 1.414
EGFR treatment −0.242 0.546 −1.051 0.567
OS primary end point −0.240 0.570 −1.095 0.615
Publication year −0.127 0.219 −0.334 0.079
Jadad scale −0.227 0.273 −0.641 0.188
Constant 246.523 0.230 −164.511 657.556
Note. Data cut D is deﬁned as phase III trials excluding those with crossover, unbalanced postprogression treatments, or insufﬁcient
information.
CI, conﬁdence interval; ECOG, Eastern Cooperative Oncology Group, performance status; EGFR, epidermal growth factor receptor; OS, overall
survival; PFS, progression-free survival.
⁎ Interaction term between PFS and data cut D is added to the model.
† High correlation between “Male” and “Adenocarcinoma” was observed (r ¼ −0.808). On the basis of collinearity diagnostics, high variance
inﬂation factor (45) and low tolerance (o0.2) values were observed. Therefore, we omitted the “Male” variable from the regression model.
V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) 9 – 1 7 15included in the primary analysis (see Appendix Figure 1 and
Appendix Tables 2 and 3 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2017.07.011). Table 1 presents basic
population characteristics in all included trials and in data cuts
deﬁned on the basis of postprogression treatments. Among all
phase III trials (n ¼ 59), 5 and 16 studies reported per-protocol and
off-protocol crossover, respectively. These studies were excluded
from data cuts A and B, respectively. Seven trials reported
unbalanced postprogression treatments and 13 trials failed
to report any information with regard to crossover or postprog-
ression treatments. These studies were later excluded from data
cut C.
In all treatment arms, combination therapy was the most
frequent intervention (74 treatment arms) and docetaxel was the
most frequent monotherapy intervention (57 treatment arms),
followed by EGFR-TKIs (erlotinib/geﬁtinib/afatinib, 45 treatment
arms) and pemetrexed (25 treatment arms). Thirty-four trials
recruited exclusively Asian patients (2874 patients). A total of 87
trials involving 10,713 patients were phase II trials, whereas 59
trials involving 32,348 patients were phase III trials. The Jadad
scale for individual trials was generally low (see Table 2 in
Supplemental Materials); this is because most of the trials were
open-label trials and sufﬁcient information about randomization
methods was not reported.
A visual examination of the funnel plots (see Appendix
Figures 2–4 in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2017.07.011) shows that the risk of publication
bias can be unlikely.
Primary Analysis
Analysis of ORR as a surrogate for OS
One hundred forty trials (41,725 patients) reported both ORR and
mOS in both treatment arms. The correlation coefﬁcient between
ΔORR and ΔOS was 0.181 (95% CI 0.016–0.337) (Table 2; Fig. 1). In
further stepwise analyses based on reported postprogression
treatments in phase III trials (data cuts A, B, C, and D),
the association between ΔORR and ΔOS becomes stronger: data
cut A, R ¼ 0.131 (95% CI 0.000–0.375); data cut B, R ¼ 0·361 (95% CI
0.103–0.573); data cut C, R ¼ 0.445 (95% CI 0.146–0.669); and datacut D, R ¼ 0.528 (95% CI 0.081–0.798). In data cut D, the upper limit
of R’s 95% CI is more than 0.7; therefore, STE was estimated to be
41% in this data cut (see Fig. 1).
Seventy-six trials (30,570 patients) reported both ORR and OS-
HR in both treatment arms. The correlation coefﬁcient between
ΔORR and log(OS-HR) was 0.172 (95% CI 0.000–0.383). In further
stepwise analyses based on reported postprogression treatments
in phase III trials (data cuts A, B, and C), association between
ΔORR and log(OS-HR) becomes stronger: data cut A, R ¼ 0.374
(95% CI 0.086–0.604); data cut B, R ¼ 0.399 (95% CI 0.104–0.629); and
data cut C, R ¼ 0.521 (95% CI 0.175–0.752). In data cut C, the upper
limit of R’s 95% CI is more than 0.7; therefore, STE was estimated
to be 55% in this data cut. This association did not achieve
statistical signiﬁcance in data cut D (see Appendix Figure 5 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2017.07.011).
Analysis of PFS as a surrogate for OS
One hundred fourteen trials (35,729 patients) reported both mPFS
and mOS in both treatment arms. The correlation coefﬁcient
between ΔPFS and ΔOS was 0.254 (95% CI 0.074–0.418) (Table 2;
Fig. 2). In further stepwise analyses based on reported postprog-
ression treatments in phase III trials (data cuts A, B, C, and D),
association between ΔPFS and ΔOS becomes stronger: data cut A,
R ¼ 0.260 (95% CI 0.000–0.502); data cut B, R ¼ 0.438 (95% CI 0.166–
0.649); data cut C, R ¼ 0.741 (95% CI 0.520–0.869); and data cut D,
R ¼ 0.778 (95% CI 0.475–0.916). In data cuts C and D, the upper
limit of R’s 95% CI is more than 0.7; therefore, STE was estimated
to be 3.7 and 4.2 incremental mPFS months, respectively, in these
data cuts (see Fig. 2).
Seventy-three trials (29,907 patients) reported both PFS-HR
and OS-HR. The correlation coefﬁcient between log(PFS-HR) and
log(OS-HR) was 0.402 (95% CI 0.190–0.579). In further stepwise
analyses based on reported postprogression treatments in phase
III trials (data cuts A, B, C, and D), association between log(PFS-
HR) and log(OS-HR) becomes stronger: data cut A, R ¼ 0.463 (95%
CI 0.185–0.672); data cut B, R ¼ 0.461 (95% CI 0.170–0.678); data cut
C, R ¼ 0.694 (95% CI 0.412–0.855); and data cut D, R ¼ 0.698 (95% CI
0.326–0.882). In data cuts C and D, the upper limit of R’s 95% CI is
more than 0.7; therefore, STE was estimated to be 0.24 and 0.22
V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) 9 – 1 716PFS-HR, respectively, in these data cuts (see Appendix Figure 6 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2017.07.011).
Additional Analysis
High correlation between “Male” and “Adenocarcinoma” was
observed (R ¼−0.808) (see Appendix Table 4 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2017.07.011). In
addition, after running collinearity diagnostics, high variance
inﬂation factor (45) and low tolerance (o0.2) values were observed
for both “Male” and “Adenocarcinoma.” Therefore, we omitted the
“Male” variable from both multivariate regression models. Table 3
presents the full multivariate linear regression model. In data cut
D, an additional 1 month of ΔPFS should translate into 1.13 ΔOS
months (95% CI 0.531–1.727), after adjustment for all other varia-
bles. Appendix Table 5 in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2017.07.011 shows the results from the
logistic regression model, in which data cut D is the dependent
variable. Studies with no crossover and reported balanced post-
progression treatments seem to be of higher quality (higher Jadad
scale) and less likely to have EGFR-TKI as investigated treatment.Discussion
This study aimed to evaluate ORR and PFS as surrogate
endpoints for OS in trials involving patients with advanced NSCLC
receiving second- and further-line therapy. The impact of cross-
over and unbalanced postprogression treatments on surrogacy
was assessed. Our ﬁndings show that crossover (per- and off-
protocol) and unbalanced postprogression treatments may bias
the association between the surrogate endpoints such as ORR or
PFS and OS. When all trials were included in the analysis, the
correlation coefﬁcients of ORR and mPFS were 0.181 (95% CI
0.016–0.337) and 0.254 (95% CI 0.074–0.418), respectively, with OS.
According to the IQWiG, this suggested that ORR and PFS are not
valid surrogate endpoints for OS [4]. Different results are seen in
analyses in which we included trials explicitly reporting balanced
postprogression treatments and excluded trials with either per-
protocol or off-protocol crossover, unbalanced postprogression
treatments, or no information (data cut D). Both ORR and PFS had
stronger associations with OS (ORR and OS: R ¼ 0.528; 95% CI
0.081–0.798; PFS and OS: 0.778; 95% CI 0.475–0.916). Nevertheless,
the upper limit of the correlation coefﬁcient CI in both cases was
higher than 0.7. Consequently, according to IQWiG recommen-
dations, the validity of ORR and PFS as surrogate endpoints for
OS is unclear [4]. In this case, the treatment effect of the
surrogate in clinical trials needs to be statistically signiﬁcant
from the calculated STE: using 95% CI or 80% CI if the 95% CI does
not lie fully above the STE. Accordingly, interventions that show
a treatment beneﬁt more than 41% ORR or 4.2 mPFS months are
expected to show a signiﬁcant OS beneﬁt with sufﬁcient
certainty.
Johnson et al. [13] studied the relationship between ORR and
OS in 191 trials involving patients with NSCLC receiving ﬁrst- and
further-line therapy. They reported a correlation coefﬁcient of
0.40 (P o 0.0001). According to their STE calculation, a treatment
beneﬁt of 18% for 750 patients, 21% for 500 patients, and 30% for
250 patients in ORR is needed to show an OS beneﬁt. The
calculated STE incorporates observations from trials in both ﬁrst-
and further-line therapy. Hotta et al. [6] identiﬁed 18 phase III
trials investigating EGFR-TKIs or anaplastic lymphoma kinase
TKIs used as a ﬁrst- or second-line treatment for NSCLC [6]. The
correlation coefﬁcient between the ORR odds ratio or PFS-HR and
the OS-HR was 0.318 and 0·483, respectively. These trials, how-
ever, reported high crossover rates [24]. Similar associationsbetween ORR or PFS and OS were observed in two other studies
[10,11]. Recently, the US Food and Drug Administration published
an endpoint validation study including 14 trials (12,567 patients)
of ﬁrst- and further-line therapy for advanced NSCLC that had
been submitted between 2003 and 2013 [12]. In the trial-level
analysis, there was no association between OS and ORR
(R2 ¼ 0.09; 95% CI 0–0.33) or between OS and PFS (R2 ¼ 0.08;
95% CI 0–0.31). Also, in that case, included trials reported
high crossover rates. In their study, no literature search was
carried out to include other trials. This may translate into a
likely risk of selection bias. On a broader scope, in a review,
commissioned by the National Institute for Health and
Clinical Excellence, of studies quantifying the relationship
between PFS and OS in advanced/metastatic cancer, the relation-
ship between PFS and OS varied considerably by cancer type and
was not consistent even within one speciﬁc cancer type [25]. In
summary, reported surrogacy of ORR or PFS to OS in literature is
poor and in agreement with the analysis we conducted on all
trials.
None of the previously published endpoint validation studies
performed a stratiﬁed analysis on the basis of crossover or
unbalanced postprogression treatments [6,10–13]. This is despite
acknowledging that crossover and postprogression treatments
may explain the observed weak associations. Thus, the reported
surrogacy of ORR or PFS to OS in patients with NSCLC may be
biased or underestimated in the published literature. Conse-
quently, the reported analyses are of little or no help to decision
makers when they should evaluate trials with a high treatment
beneﬁt on a surrogate endpoint. Exclusion of trials with crossover
and/or unbalanced subsequent therapies appears to be a sub-
stantial factor to identify highly reliable trials. Furthermore, on
the basis of the additional analysis, the existence of crossover
alone seems to be the key factor that may have biased the PFS-OS
relationship. The relationship between PFS and OS remained
statistically signiﬁcant after the adjustment for other available
variables in our data set (Table 3).
This study has some limitations. We have not searched for
unpublished studies. Nevertheless, we believe that we did not
miss relevant studies for various reasons. First, information
about crossover or postprogression treatments is mostly reported
in full study reports. Thus, including, for example, an abstract
database would not have added to our conclusion because all
retrieved hits would have been excluded at the end. In addition,
according to the funnel plots, publication bias is unlikely. Second,
excluding studies from the main analysis on the basis of cross-
over or unbalanced postprogression treatment may have intro-
duced selection bias. Nevertheless, the population characteristics
of the trials included in different analyses appear to be compa-
rable (Table 1), minimizing the risk of selection bias. Third, the
populations, settings, and interventions included are heteroge-
neous. This might also affect the association between the
surrogate and the true endpoints. On the basis of the multivariate
model, however, the conclusion that crossover and unbalanced
postprogression treatments may bias such relationship still
holds. Only median age may have a minimal impact. Fourth,
the deﬁnition and assessor of response is not consistent across
studies and we did not account for that in our analysis. In
previous endpoint literature, however, presented analyses were
not stratiﬁed by response deﬁnition [6,10–13]. In addition, strat-
ifying our analysis on the basis of response criteria would have
impeded carrying out analysis in different data cuts.
Applying our methodology, that is, stratifying studies by
crossover and postprogression treatments, for other surrogate
endpoints in NSCLC (e.g., time to progression and duration of
response), in different line settings (e.g., ﬁrst-line NSCLC) or in
other tumor types, is warranted. In other tumor types, it is likely
that crossover and unbalanced postprogression treatments may
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endpoints in these settings. Nevertheless, the extent of such
likely bias needs to be further assessed.Conclusions
Crossover and postprogression treatments may bias the quantita-
tive relationship between surrogate endpoints (ORR/PFS) and OS.
Therefore, the validity of ORR and PFS as surrogate endpoints for
OS might be better estimated in trials that do not allow for
crossover and that report balanced postprogression treatments.
In second- and further-line therapy of advanced NSCLC, the
validity of ORR and PFS as surrogate endpoints for OS is unclear,
and a large effect size is needed to predict OS beneﬁt with sufﬁcient
certainty. Trials that show a statistically signiﬁcant treatment
effect of 41% ORR or 4.2 mPFS months are expected to show a
signiﬁcant OS beneﬁt with sufﬁcient certainty. Further investiga-
tion of such methodology for other surrogate endpoints, in ﬁrst-
line therapy and in other tumor types and settings, is warranted.Acknowledgment
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